Aztreonam: clinical and pharmacological characteristics at the present stage

One of the urgent problems modern health care is growing resistance microorganisms to antibiotics, including carbapenems, which until recently were considered as drugs choice in treatment life-threatening infections. Enzymatic inactivation through production carbapenemase, main mechanism Gram-negative bacteria. The these infections presents significant difficulties due extremely limited arsenal effective drugs. Aztreonam currently first and only monocyclic beta-lactam antibiotic, monobactam, used clinical practice for caused by gram-negative data obtained vitro observations are presented. These results justify use drug a number «problem» pathogens, those resistant carbapenems. has high potential should be treat patients with nosocomial – focus its bacteria-producers metallo-beta-lactamases.